Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366829 · ClinicalTrials.gov registry record · Phase 2
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
A Phase 2 study of Carcinoma, Hepatocellular and Liver Cell Carcinoma, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT05366829: Recruiting Phase 2 study of Carcinoma, Hepatocellular and Liver Cell Carcinoma, sponsored by Rutgers, The State University of New Jersey.
NCT05366829 is a Phase 2 study of Carcinoma, Hepatocellular and Liver Cell Carcinoma that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 35 participants, below the 611-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05366829, a Phase 2 study of Carcinoma, Hepatocellular and Liver Cell Carcinoma, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.
Primary Outcome
Number of participants experiencing adverse events grade three or higher, as defined by Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0). Severity is a measure of intensity (eg, grade of a specific AE, mild \[Grade 1\], moderate \[Grade 2\], severe \[Grade 3\], or life-threatening \[Grade 4\]), whereas seriousness is classified by the criteria based on the regulatory definitions. Seriousness serves as the guide for defining regulatory reporting obligations from the Inv
Conditions Studied
Interventions
- DRUG Tislelizumab
Study Locations (2)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
What NCT05366829 shows while recruiting
NCT05366829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 611-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 1 intervention - of which Tislelizumab is the first listed.
NCT05366829 reports a single indexed study location in New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT05366829 about?
NCT05366829 is a clinical study titled "Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma". The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participa...
What is the current status of trial NCT05366829?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-07-25. Estimated completion is 2027-06-01.
What conditions does trial NCT05366829 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular, Liver Cell Carcinoma.
What interventions are being tested in trial NCT05366829?
The interventions under investigation include: Tislelizumab (DRUG).
Who is sponsoring clinical trial NCT05366829?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05366829 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05366829's enrollment target sits among peer trials
35 22nd of 27 higher than 6 of 27 other Carcinoma, Hepatocellular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 2
-
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
COMPLETED · Phase 2
-
A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
COMPLETED · Phase 2
-
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 2
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
-
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI